SanBio secures ¥1bn credit line for drug commercialization

SanBio announced a ¥1.0 billion committed credit line with MUFG Bank, effective July 2025 and expiring February 2027. The facility will fund working capital for commercializing AKUUGO Suspension for Intracranial Implantation.

AKUUGO received conditional approval in July 2024, with SanBio planning a partial change application. This supplements existing ¥1.0 billion credit lines with Mizuho Bank and Resona Bank, bringing total committed facilities to ¥3.0 billion for manufacturing, distribution and marketing infrastructure.